Sat Aug 1 15:45:12 SGT 2015  
SINGAPORE
GUM™
    Genital Warts
SINGAPORE GUM™
HIV PEP (post-exposure prophylaxis): Stop HIV infection within 3 days after unprotected sex.
HIV test: 20 minute rapid test to accurately detect HIV infection 28 days after unprotected sex.
STD testing: Full & comprehensive sexually transmitted disease testing.

Genital Warts | SINGAPORE GUM™

Summary

Genital Warts | SINGAPORE GUM™ @singaporegum_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE GUM™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital Warts | SINGAPORE GUM™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Genital HPV types, cancer risk, vaccine and test coverage
Type
Species
Risk
Cervarix
Gardasil
Gardasil-9
DigeneHR
DigenePS
CobasHPV
Digene
HybriBio
PapilloCheck
InnoLiPA
LinearArray
61 3 L ----------+-
72 3 L ----------+-
81 3 L -------+--+-
83 3 L ----------+-
84 3 L ----------+-
62 3 L ----------+-
CP6108 3 L ----------+-
71 15 L ---------++-
26 5 H ---------++-
51 5 H ---+-++++++-
69 5 H ---------++-
82 5 H --------+++-
IS39 5 H ----------+-
18 7 H +++++++++++-
39 7 H ---+-++++++-
45 7 H --+++++++++-
59 7 H ---+-++++++-
68 7 H ---+-++++++-
70 7 H --------+++-
53 6 H -------++++-
56 6 H ---+-++++++-
66 6 H -----+-++++-
54 13 L ---------++-
42 1 L ------+++-+-
40 8 L --------+++-
43 8 L ------++++--
6 10 L -++---+++++-
11 10 L -++---+++++-
44 10 L ------++++--
74 10 L ---------+--
16 9 H +++++++++++-
31 9 H --++-++++++-
33 9 H --++-++++++-
35 9 H ---+-++++++-
52 9 H --++-++++++-
58 9 H --++-++++++-
67 9 H ----------+-
73 11 H --------+++-

Legend: 71 (CP 8061), 73/MM9, 81 (CP 8304), 82 (MM4), 82 (IS 39), 83 (MM7), 84 (MM8), 89 (CP 6108)

References

Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $135/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute rapid HIV test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute rapid HIV test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Oregon has a low STD vaccination rate
Fri, 31 Jul 2015 20:58:46 +0100 | bizjournals.com Health Care:Biotechnology headlines
Oregon is about average in the U.S. when it comes to vaccinating adolescents against human papillomavirus, or HPV, but many teens still aren’t getting vaccinated, and that puts them at risk for cancer of the cervix, among other cancers.

Detection and genotyping of HPV in women with indeterminate cytology and low-grade squamous intraepithelial lesions
Fri, 31 Jul 2015 15:58:26 +0100 | Jornal Brasileiro de Patologia e Medicina Laboratorial
Conclusion: The presence of high-risk HPV in women with old cervical lesions, whether they have evolved or not, indicates the need to improve patient monitoring and surveillance. RESUMO Introdução: O papilomavírus humano (HPV) é o principal fator de risco relacionado com câncer cervical. A identificação precoce de tipos de HPV de alto risco em cérvice normal ou com lesões precursoras pode auxiliar a prevenir que essas lesões progridam para neoplasias malignas. Objetivos: Este estudo teve como objetivo detectar e genotipar o HPV em mulheres com resultado citológico de lesão intraepitelial escamosa de baixo grau (LSIL) e células escamosas atípicas de significado indeterminado (ASC-US). Métodos: Mulheres diagnosticadas com LSIL e ASC-US foram selecionadas a partir do arquivo de...

Wow, Americans Really Aren't Fans Of The Life-Saving HPV Vaccine
Fri, 31 Jul 2015 15:46:11 +0100 | Science - The Huffington Post
By Kylie GumpertJuly 30 (Reuters) - The percentage of U.S. teenagers vaccinated against the human papillomavirus increased slightly in 2014, but the rate lags behind other immunizations, the Centers for Disease Control and Prevention said on Thursday.The HPV vaccine, sold as Gardasil by Merck & Co and Cervarix by GlaxoSmithKline, protects against the most common sexually transmitted infection. Each year, 27,000 people nationwide are diagnosed with a cancer caused by the virus, including cancers of the cervix, penis, anus and throat.The CDC said the percentage of girls between 13 and 17 years old who received at least one dose of the vaccine increased by 3.3 percentage points to 60 percent. For boys, the rate increased 8.1 percentage points to 41.7 percent.In that same age group, 39.7 p...

Comparative analysis of cervical cytology and human papillomavirus genotyping by three different methods in a routine diagnostic setting
Fri, 31 Jul 2015 07:16:30 +0100 | European Journal of Cancer Prevention
Application of Bethesda guidelines on cervical cytology involves human papillomavirus (HPV) determinations on all ASC-US and ASC-H results. We compared HPV DNA results in view of the eventual development of a cervical intraepithelial neoplasia lesion determined either on cytology or histology. A total of 214 liquid-based cytology samples were analysed. Three different HPV DNA methods were applied: the Abbott RealTime High Risk HPV test, INNO-Lipa HPV Genotyping Extra and Full Spectrum PCR HPV Amplification and Detection/Genotyping System by Lab2Lab Diagnostic Service. A comparison of these three methods showed full concordance only for 49 samples (23%), and 27 (13%) of the samples were discordant in indicating the presence of the high-risk HPV type. Out of 214 patients, 88 were selected wh...

The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis
Fri, 31 Jul 2015 00:00:00 +0100 | Virchows Archiv
Abstract

HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status
Fri, 31 Jul 2015 00:00:00 +0100 | Cancer Cytopathology
CONCLUSIONSA reduction in the diagnostic accuracy of Pap cytology was observed when revealing patients' cervical HPV status, possibly due to a heightened awareness of potential abnormalities, which led to more false‐positive results. Cancer (Cancer Cytopathol) 2015. © 2015 American Cancer Society. (Source: Cancer Cytopathology)

CDC Releases Additional Guidance for 9-Valent HPV Vaccine (FREE)
Fri, 31 Jul 2015 00:00:00 +0100 | Physician's First Watch current issue
By Amy Orciari Herman

Negative emotions and stigma associated with a human papillomavirus test result: A comparison between human papillomavirus-positive men and women
Fri, 31 Jul 2015 00:00:00 +0100 | Journal of Health Psychology
In this study, we found that women infected with human papillomavirus (n = 154) experienced a greater degree of negative emotions and stigma than human papillomavirus–infected men (n = 190). Among women, younger age and less education were associated with greater expression of negative emotions and stigma. Conversely, being single was significantly associated with a greater degree of negative emotions and stigma beliefs among men. These findings suggest the need to re-frame messages that both men and women receive regarding human papillomavirus. (Source: Journal of Health Psychology)

Human papillomavirus DNA in pharyngeal scrapes as a marker of HPV-related squamous cell cancer of the oropharynx
Fri, 31 Jul 2015 00:00:00 +0100 | Journal of Clinical Virology
It has recently become evident that infection with high-risk human papillomavirus (HR-HPV) is etiologically linked to a subgroup of head and neck squamous cell cancer (HNSCC). Oropharyngeal carcinomas (OPCs) were found to have a relatively high prevalence of HR-HPV DNA (18.3–57%), exceeding half of all carcinomas in the tonsillar region [1,2]. Reviewing SEER data for the last 30 years (1973–2004) showed changing demographics of patients with cancer arising from the mucosa of the oral cavity and oropharynx. (Source: Journal of Clinical Virology)

Researching and Respecting the Intricacies of Isolated Communities
Thu, 30 Jul 2015 22:38:15 +0100 | Rural publications via the Rural Assistance Center
Examines parental perceptions of the human papillomavirus vaccine in three rural Georgia counties, and describes a method for conducting successful nursing research in rural areas. Includes statistics with breakdowns by age, sex, race, and children's grade levels. (Source: Rural publications via the Rural Assistance Center)